Is Borregaard (OB:BRG) Fairly Valued As Cost Cuts Offset Impairment And Mixed Segment Results?
Mixed segment performance and impairment put Borregaard (OB:BRG) in focus
Borregaard (OB:BRG) has drawn investor attention after reporting stronger results in its BioMaterials and Fine Chemicals segments, softer performance in BioSolutions, and a NOK 337 million impairment on its investment in Alginor ASA.
At the same time, the company has launched a cost improvement programme targeting yearly savings of NOK 150 million by 2028. This adds a new element for investors to weigh alongside recent share price moves.
See our latest analysis for Borregaard.
Recent trading shows a sharp short term rebound in Borregaard, with a 1 month share price return of 13.4% after a weaker period in which the year to date share price return is down 18.2% and the 1 year total shareholder return declined 15.3%. This suggests sentiment has improved, while longer term performance remains mixed.
If this mix of segment results and cost cuts has you thinking about where else to deploy capital, it could be a good moment to scan for other resilient industrial and materials names through the 106 top founder-led companies
Borregaard now trades at a discount of about 9% to analyst targets and an indicated 28% to intrinsic value, even after the recent rebound. This raises a simple question: is the market’s caution still warranted by the recent setbacks?
Most Popular Narrative: 8% Undervalued
The most followed valuation narrative for Borregaard places fair value at NOK174 per share, compared with the last close at NOK160.8, which frames the current discount.
Strong sales in the agriculture segment, driven by the increasing demand for green and biocontrol products, are expected to positively impact revenue growth and EBITDA margins. The favorable product mix in BioSolutions, particularly with high value specialty products, is anticipated to boost overall earnings and contribute to higher net margins.
Want to see what earnings profile sits behind that fair value for Borregaard? The narrative leans heavily on rising margins, steadier revenue growth and a lower future profit multiple. Curious how those moving parts fit together into one valuation story?
Result: Fair Value of NOK174 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Borregaard’s story can still be knocked off course if higher wood and logistics costs persist, or if tariffs and trade tensions start to bite harder.
Find out about the key risks to this Borregaard narrative.
Another View on Borregaard’s valuation
The earlier fair value narrative paints Borregaard as undervalued, but the current P/E of 29.2x tells a tougher story. That multiple is higher than the European Chemicals industry at 19.6x, above the peer average of 19.9x, and above a fair ratio estimate of 22.5x.
In practice, that means anyone buying today is paying a richer price than both sector and peer benchmarks, while also sitting above the level the market could move towards if expectations cool. The question is whether you believe the forecast earnings growth is strong enough to justify that premium over time.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals around Borregaard have you unsure, look at the numbers directly, consider the trade offs, and see the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Borregaard?
If Borregaard has sharpened your focus on quality and price, do not stop here. Broaden your watchlist with a few targeted stock ideas from the Simply Wall St screener.
- Spot potential bargains early by scanning screener containing 506 high quality undiscovered gems that pair solid fundamentals with less crowded investor attention.
- Strengthen your core holdings by reviewing solid balance sheet and fundamentals stocks screener (417 results) that aim for resilient finances and support through different market conditions.
- Prioritize capital protection by checking 292 resilient stocks with low risk scores that may offer steadier return profiles with fewer surprises.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com